Nomura Securities Maintains a 'Reduce' on Texas Instruments (TXN); Q2 Review
Get Alerts TXN Hot Sheet
Price: $279.58 +2.25%
Rating Summary:
24 Buy, 22 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
24 Buy, 22 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Nomura Securities maintains a 'Reduce' on Texas Instruments (NYSE: TXN) price target of $26.00.
Nomura analyst, Romit Shah,�says, "Reported 2Q earnings slightly above reduced expectations. Weak Q3 guidance backs our view that end customers are reducing build forecasts for back-to-school and the holiday season. We believe the guide for Q3 would have been worse if not for ongoing supply constraints at the Miho fab. We believe Q3 is not likely the last estimate cut. Our estimates are largely unchanged at $0.60 for 3Q11, $2.30 ($2.28 previously) for 2011, and $2.38 for 2012 (consensus at $2.67)."
For more ratings news on Texas Instruments click here and for the rating history of Texas Instruments click here.
Shares of Texas Instruments closed at $31.47 yesterday.
Nomura analyst, Romit Shah,�says, "Reported 2Q earnings slightly above reduced expectations. Weak Q3 guidance backs our view that end customers are reducing build forecasts for back-to-school and the holiday season. We believe the guide for Q3 would have been worse if not for ongoing supply constraints at the Miho fab. We believe Q3 is not likely the last estimate cut. Our estimates are largely unchanged at $0.60 for 3Q11, $2.30 ($2.28 previously) for 2011, and $2.38 for 2012 (consensus at $2.67)."
For more ratings news on Texas Instruments click here and for the rating history of Texas Instruments click here.
Shares of Texas Instruments closed at $31.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Nomura, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share